網頁

醫藥 - SAPANE第19屆職業發展研討會3/18

SAPA-NE Career Development Symposium Career in Biotech Start-up and Entrepreneurship 
– Translating Research into Business, Ideas/Technology into Pipelines/Products 
MIT Maclaurin Building 4-370 182 Memorial Drive (Rear), Cambridge, MA 02138 
Saturday 1-6 PM, March 18, 2017 

Welcome to attend the 19th SAPA-NE Career Development Symposium on Saturday, March 18th, 2017 at MIT Maclaurin Building. The biopharma industry entrepreneurs and the experts in legal and venture capital will share their experience and perspective in successfully founding, managing or investing in biotech start-up(s) and overall insight and visions on scientific innovation and biotech entrepreneurship. The meeting will also provide the attendees an excellent opportunity to network with biopharmaceutical professionals around Boston area and to access some new job openings posted onsite. The Plenary Session Speakers include: Yi Zhang, Ph.D., a HHMI Investigator and Professor of HMS and BCH, and a co-founder of Epizyme Joy Alamgir, Entrepreneur, Founder, EVP and CSO of Consilience Software, A Xerox Company Chong Xu, Ph.D., Associate, F-Prime Capital Partners, Boston Ruhong Jiang, Ph.D., a co-founder, president and CEO of Applied Stem Cell Fang Xie, Ph.D., Of Counsel, Greenberg Traurig, LLP, Boston Follow by a panel discussion with all speakers plus Wei Zhao, Ph.D., Associate, Wuxi Healthcare Venture Online registration: http://sapa-neweb.org/CDS2017.php This event is free for SAPA-NE members and MIT students; $30 for non-members; $15 for students. (coorganizer MIT-CHIEF) SAPA-NE Career Development Symposium Organizing Committee 

U.S. Department of Homeland Security to Keynote at Biosurveillance Integration,
part of Biodefense World Summit

The national strategy for biosurveillance calls for a coordinated approach for threats to public health and safety, bringing together federal, state and local governments; private sector, nongovernmental organizations and international partners to enhance existing biosurveillance capabilities and develop new ones that provide decision makers and responders with the essential information to manage these threats. This strategy recognizes that a well-integrated national biosurveillance enterprise can save lives by providing essential information for better decision making at all levels. The Sixth Annual Biosurveillance Integration conference will address implementation strategies for the national strategy for biosurveillance identified core functions.
Luther LindlerBiosurveillance to Protect the Homeland
Luther Lindler, Ph.D., Senior Scientist (ST), Biological Programs, Chemical and Biological Defense Division Science and Technology Directorate, U.S. Department of Homeland Security
One of the Department of Homeland Security's (DHS) responsibilities is to protect the U.S. from a biological attack. The Science and Technology Directorate, through the Chemical and Biological Defense Division (CBD), has developed a Real Time Threat Awareness biosurveillance program that integrates information data streams with new detection technologies. This presentation will discuss the interest areas and progress DHS CBD is making toward building a 21st century biosurveillance program.

Dr. Lindler joined the DHS Science and Technology Directorate in October 2003 as a Senior Science Advisor. Dr. Lindler currently serves the Senior Scientist for biological programs within the chemical and biological defense division where he provides expertise to both DOD as well as DHS about current infectious disease threats from a global perspective. He currently serves on the Joint Influenza Surveillance Working Group for DOD, is the DOD representative to the Interagency Influenza Diagnostics Working Group, as well as senior advisor to DOD Health Affairs on technical diagnostic issues that affect force health protection. He currently manages several projects related to infectious disease for the AFHSC. The most notable is to bring forward deployed rapid molecular diagnostics to DOD forward deployed forces. He also serves on the National Biodefense Analysis and Countermeasures Center review committee for DHS S&T and has participated in the national Material Threat Assessment and Biological Risk Assessment programs. His first position within DHS was as the Science Advisor for the NBACC. He helped plan the NBACC forensics and threat characterization programs as well as the first DHS laboratory building on the Fort Detrick National Biodefense Campus. Before joining DHS, Dr. Lindler was a leader in the US Army Biodefense program. He was a principle investigator at the Walter Reed Army Institute of Research leading a team of professionals studying the pathogenesis of the plague bacterium. He served on the Army’s plague vaccine steering committee and the emerging threats steering committee within the Biodefense program. The peak of his career with the Army culminated with his senior editorship of the well-acclaimed Biodefense book entitled, “Biological Weapons Defense; Infectious Diseases and Counterbioterrorism.” Dr. Lindler was a postdoctoral fellow in the laboratory of Dr. Susan Straley at the University of Kentucky in Lexington from 1987 until 1989. Dr. Lindler received his Ph.D. in Microbiology from the Medical College of Virginia in 1987, his Masters of Science in Microbiology from Clemson University in 1981 and his Bachelor’s of Science in Medical Technology from Lenoir Rhyne College in North Carolina in 1978.




WuXi NextCODE Appoints Hannes Smarason as CEO, John Long as CFO, and Alex Fowkes as COO

Appointments bolster global business expansion, operational integration and independent strategic development

NEWS PROVIDED BY
WuXi NextCODE 
Feb 28, 2017, 13:00 ET

SHANGHAICAMBRIDGE, Mass. and REYKJAVIK, IcelandFeb. 28, 2017 /PRNewswire/ -- WuXi NextCODE, a WuXi AppTec group company and the contract genomics organization enabling precision medicine worldwide, today announced that the company's chief operating officer Hannes Smarason has been appointed as the company's chief executive officer, and WuXi AppTec senior vice presidents John Long and Alex Fowkes have been named chief financial officer and chief operating officer, respectively.
"WuXi NextCODE is executing on its vision to enable anyone to use the genome to advance health and wellness worldwide," said Dr Ge Li, founder and chairman of WuXi AppTec group and chairman of WuXi NextCODE. "It is also positioning itself as the data management platform at the heart of the genomics revolution and what may become the world's largest data ecosystem. Hannes, John and Alex have the breadth of vision and proven executive capabilities to carry out this strategy and advance the company to the next level."





"This is an exciting time at WuXi NextCODE, as we work on leading projects in every facet of genomics and advance a global standard for the way genomic data is organized, mined and shared," said Mr Smarason. "John and Alex's leadership and experience in life sciences finance and operations, and in the recent independent listing of other WuXi AppTec companies, will be invaluable as we grow our business and forge our own strategic path. We are very pleased to have them join our team and offer them a warm welcome to WuXi NextCODE."
Hannes Smarason co-founded NextCODE Health in 2013 as a spinout from deCODE genetics. He oversaw NextCODE's acquisition by WuXi AppTec in 2015 and its merger with the WuXi Genome Center to create WuXi NextCODE. He served as COO until January 2017 and as CEO will lead the company's overall business and corporate strategy.
John Long has served as WuXi AppTec's senior vice president of finance since 2013. He was actively involved in WuXi AppTec's privatization from NYSE in 2015 and played important roles in WuXi AppTec's subsequent corporate restructuring, supporting WuXi Biologics's recent IPO filing process in Hong Kong as well as private placements in the China capital market. John has over twenty years' experience in financial management, investment and operations in the US, China and Singapore, and prior to joining WuXi AppTec served in senior roles at Willis Group, Tyco International and Lucent Technologies. In addition to finance and operations leadership, he will provide WuXi NextCODE with global expertise in governance, reporting, strategic planning, treasury and tax. John holds a bachelor's degree in economics from the University of International Business and Economics in Beijing and received his MBA from Wharton School of Business at University of Pennsylvania.
Alex Fowkes has twenty years experience in the life science industry in operations, business development, strategy and legal roles. He joined WuXi AppTec in 2012 initially to lead corporate development and then most recently serving as senior vice president of commercial operations. Prior to WuXi Alex served in a variety roles for Pfizer in the US, UK, Australia and China over 14 years.
About WuXi NextCODEWuXi NextCODE is a fully integrated global contract genomics organization. With offices in ShanghaiKendall Square in Cambridge, Massachusetts; and Reykjavik, Iceland, we offer comprehensive services that enable population, precision medicine, diagnostics and wellness initiatives and enterprises to use the genome to improve health around the world. Our capabilities span study design, sequencing, secondary analysis, storage, and interpretation and scalable analytics – all backed by the most proven and widely used technology for organizing, mining and sharing genome sequence data. We are also applying the same capabilities to advance a growing range of sequence-based tests and scans in China. WuXi NextCODE is a WuXi AppTec Group company. Visit us on the web at wuxinextcode.com.